Imagine this: In a world where the U.S. government is pushing hard for lower drug prices to make life-saving medications more affordable, pharmaceutical giants are quietly planning to hike costs on hundreds of essential treatments. It's a stark contradiction that leaves many wondering just how committed these companies really are to public health—and that's exactly what we're diving into today. Buckle up, because this story isn't just about numbers; it's about the tug-of-war between profit and people.
Exclusive Insight: Pharmaceutical Firms Increase U.S. Prices on Over 350 Medications Amid Trump's Push for Reductions
- Overview
Involved Corporations
Rise in Price Adjustments Compared to the Previous Year
Average List Price Hike Stands at 4%, Matching Projections for 2025
Encompasses Five Manufacturers Who Negotiated Pricing Agreements with the Trump Administration
NEW YORK, December 31 (Reuters) - Despite intense pressure from the Trump administration to reduce costs, pharmaceutical companies are set to elevate U.S. prices on no fewer than 350 branded drugs, encompassing vital vaccines for illnesses like COVID-19, RSV, and shingles, along with the widely used cancer therapy Ibrance. This revelation comes from exclusive data shared by the healthcare research organization 3 Axis Advisors.
The tally of planned price escalations for 2026 surpasses that of the corresponding period last year, when firms announced intentions to increase prices on more than 250 medications. This year's average price boost hovers around 4%, aligning closely with forecasts for 2025.
These upward adjustments exclude any rebates provided to pharmacy benefit managers or other negotiated discounts, offering a clearer picture of the raw list price changes.
COMPANIES ALSO IMPLEMENTING PRICE REDUCTIONS ON CERTAIN MEDICATIONS
On a parallel note, these same pharmaceutical entities are preparing to lower list prices on approximately nine drugs. Notably, this includes a substantial reduction exceeding 40% on Boehringer Ingelheim's diabetes medication Jardiance, alongside three associated therapies.
Boehringer Ingelheim and Eli Lilly (LLY.N), which co-market Jardiance, have yet to provide responses to inquiries regarding the rationale behind these price drops.
Jardiance ranks among the top 10 drugs for which the U.S. government successfully negotiated reduced prices under the Medicare program for individuals aged 65 and above starting in 2026. Through these discussions, Boehringer and Lilly agreed to cut the Jardiance price by a remarkable two-thirds.
American consumers currently bear the highest burden for prescription drug costs globally, often shelling out nearly three times what residents in other advanced economies pay. President Trump has been vocal in urging pharmaceutical companies to align their prices with those in comparably affluent nations.
Yet, these planned increases across 350 medications unfold against the backdrop of Trump's agreements with 14 drug manufacturers to adjust prices for select drugs within the Medicaid program, which supports low-income Americans, as well as for direct cash purchases. Companies like Pfizer (PFE.N), Sanofi (SASY.PA), Boehringer Ingelheim, Novartis (NOVN.S), and GSK (GSK.L) are among those involved—and they are simultaneously gearing up for price hikes on other products effective January 1.
"These agreements are often presented as groundbreaking shifts, but in reality, they merely scratch the surface of the core factors inflating prescription drug costs in America," commented Dr. Benjamin Rome, a health policy expert at Brigham and Women's Hospital in Boston.
Dr. Rome further explained that companies appear to be optimizing their pricing strategies by securing hidden discounts with health insurers and drug benefit providers, all while establishing separate rates for out-of-pocket consumer purchases. To put this in simpler terms, think of it like a store advertising a sale on one item to draw you in, while quietly raising prices on others in the background.
A spokesperson for the Department of Health and Human Services (HHS) chose not to provide commentary on the matter.
ALIGNING WITH INFLATIONARY PRESSURES
Pfizer leads the pack with the highest number of proposed list price increases, affecting roughly 80 distinct medications. This includes oncology treatments like Ibrance, migraine remedies such as Nurtec, and COVID-19 therapies like Paxlovid, plus certain hospital-administered options like morphine and hydromorphone.
The majority of Pfizer's hikes fall under 10%, with one exception: a 15% uptick on the COVID-19 vaccine Comirnaty. Meanwhile, some of their more affordable hospital drugs have seen escalations of over four times their previous levels.
In a company statement, Pfizer noted that they have moderated the average list price of their cutting-edge medications and vaccines for 2026 to stay below the general inflation rate.
"This measured adjustment is essential to fund ongoing research and development, ensuring we can innovate new treatments while managing rising operational expenses," Pfizer elaborated.
Historically, the U.S. has seen steeper drug price hikes, but criticism from policymakers and emerging regulations—like penalties for Medicare price increases exceeding inflation—have prompted companies to moderate their approaches.
For instance, the European-based GSK intends to raise prices on about 20 drugs and vaccines, ranging from 2% to 8.9%. The firm emphasized its dedication to fair pricing, stating that these adjustments are crucial for fueling scientific breakthroughs.
Sanofi and Novartis did not reply to requests for comments.
Expect additional price modifications in the early days of January, a period traditionally marked by the most significant drug pricing announcements from the industry.
3 Axis Advisors is a consultancy that collaborates with pharmacist associations, health insurers, and various groups tied to the pharmaceutical sector on matters of drug pricing and supply chain dynamics. It is affiliated with and shares personnel with the non-profit organization 46brooklyn, focused on drug pricing transparency.
Reported by Michael Erman; Edited by Caroline Humer
Our Standards: The Thomson Reuters Trust Principles. (https://www.thomsonreuters.com/en/about-us/trust-principles.html)
But here's where it gets controversial: Are these price hikes a necessary evil to drive innovation, or are they just another way for big pharma to line their pockets while the government plays catch-up? Critics like Dr. Rome argue these deals with Trump are more cosmetic than substantive, potentially allowing companies to play both sides—cutting prices in negotiated deals while hiking them elsewhere. And this is the part most people miss: Even as the administration touts victories, the bulk of American patients might still face escalating costs, widening the gap between wealthy nations and ours. What do you think—should the government enforce stricter controls, or are these hikes justified for funding new cures? Share your thoughts in the comments below; I'd love to hear if you agree with the deals or see them as insufficient. Is there a better way to balance profit with access to essential meds?
